Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 20 | 2025 | 324 | 2.950 |
Why?
|
| Hydroxyurea | 2 | 2020 | 84 | 0.700 |
Why?
|
| Recombinases | 3 | 2025 | 27 | 0.620 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2025 | 64 | 0.490 |
Why?
|
| Glioma | 4 | 2007 | 475 | 0.380 |
Why?
|
| Erythrocyte Aging | 1 | 2011 | 4 | 0.350 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2024 | 136 | 0.350 |
Why?
|
| Antisickling Agents | 1 | 2011 | 19 | 0.340 |
Why?
|
| Acetamides | 1 | 2011 | 44 | 0.340 |
Why?
|
| Hemolysis | 1 | 2011 | 102 | 0.340 |
Why?
|
| Cytapheresis | 1 | 2009 | 1 | 0.320 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 190 | 0.300 |
Why?
|
| beta-Globins | 2 | 2025 | 9 | 0.290 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 135 | 0.290 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2007 | 7 | 0.270 |
Why?
|
| Brain Stem Neoplasms | 1 | 2007 | 40 | 0.260 |
Why?
|
| Cerebral Infarction | 3 | 2014 | 42 | 0.240 |
Why?
|
| Child, Preschool | 17 | 2024 | 14350 | 0.240 |
Why?
|
| Pain | 4 | 2017 | 429 | 0.230 |
Why?
|
| Child | 23 | 2024 | 25070 | 0.230 |
Why?
|
| Alleles | 3 | 2025 | 1611 | 0.230 |
Why?
|
| Hemoglobin, Sickle | 4 | 2021 | 19 | 0.230 |
Why?
|
| Neonatal Screening | 2 | 2017 | 190 | 0.220 |
Why?
|
| Blood Transfusion | 3 | 2021 | 285 | 0.210 |
Why?
|
| Magnesium Sulfate | 1 | 2014 | 51 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 1178 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 3573 | 0.200 |
Why?
|
| Menorrhagia | 1 | 2024 | 81 | 0.200 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 96 | 0.200 |
Why?
|
| Adolescent | 18 | 2024 | 19942 | 0.200 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 130 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 33 | 0.190 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1018 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 166 | 0.180 |
Why?
|
| Angola | 2 | 2018 | 6 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 222 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 223 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 450 | 0.170 |
Why?
|
| Humans | 34 | 2025 | 125950 | 0.160 |
Why?
|
| Malaria | 1 | 2021 | 97 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 172 | 0.160 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 64 | 0.160 |
Why?
|
| Iron | 1 | 2022 | 295 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2010 | 119 | 0.150 |
Why?
|
| Hemoglobins | 2 | 2022 | 307 | 0.140 |
Why?
|
| Hematology | 1 | 2018 | 40 | 0.140 |
Why?
|
| Pediatrics | 2 | 2018 | 1205 | 0.140 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 73 | 0.140 |
Why?
|
| Blood Pressure | 2 | 2014 | 1302 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2010 | 280 | 0.130 |
Why?
|
| Algorithms | 1 | 2024 | 1635 | 0.130 |
Why?
|
| Anemia | 1 | 2021 | 330 | 0.130 |
Why?
|
| Female | 19 | 2024 | 67908 | 0.130 |
Why?
|
| Paper | 1 | 2017 | 7 | 0.130 |
Why?
|
| Male | 18 | 2024 | 62094 | 0.130 |
Why?
|
| Platelet Count | 2 | 2022 | 129 | 0.130 |
Why?
|
| Quality Improvement | 3 | 2024 | 673 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2743 | 0.120 |
Why?
|
| Infant | 9 | 2024 | 12782 | 0.120 |
Why?
|
| Ikaros Transcription Factor | 1 | 2015 | 29 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 309 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 294 | 0.120 |
Why?
|
| Patient Care | 2 | 2018 | 99 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 998 | 0.110 |
Why?
|
| Magnesium | 1 | 2015 | 118 | 0.110 |
Why?
|
| Quality of Life | 3 | 2017 | 2011 | 0.110 |
Why?
|
| Length of Stay | 3 | 2015 | 1314 | 0.110 |
Why?
|
| Body Height | 1 | 2014 | 190 | 0.100 |
Why?
|
| Neoplasms | 2 | 2014 | 2838 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 2919 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8374 | 0.090 |
Why?
|
| Global Health | 1 | 2017 | 604 | 0.090 |
Why?
|
| Young Adult | 6 | 2023 | 9596 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2024 | 16782 | 0.090 |
Why?
|
| beta-Thalassemia | 1 | 2011 | 26 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2015 | 1591 | 0.090 |
Why?
|
| Prognosis | 3 | 2024 | 4691 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1224 | 0.090 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 15 | 0.090 |
Why?
|
| Acute Chest Syndrome | 1 | 2011 | 10 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 575 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 722 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 5089 | 0.090 |
Why?
|
| Hematocrit | 1 | 2011 | 107 | 0.080 |
Why?
|
| Body Weight | 1 | 2014 | 968 | 0.080 |
Why?
|
| HIV Infections | 1 | 2022 | 1955 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 735 | 0.080 |
Why?
|
| Chest Pain | 1 | 2009 | 93 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 280 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 523 | 0.070 |
Why?
|
| Brain | 1 | 2010 | 3021 | 0.070 |
Why?
|
| Risk Factors | 5 | 2024 | 10355 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 786 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2014 | 536 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2023 | 969 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 238 | 0.070 |
Why?
|
| Syndrome | 1 | 2009 | 1114 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1164 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 1217 | 0.060 |
Why?
|
| Neurologic Examination | 1 | 2007 | 191 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 485 | 0.060 |
Why?
|
| Adult | 6 | 2024 | 30262 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 555 | 0.050 |
Why?
|
| Hospitals, Special | 1 | 2014 | 12 | 0.050 |
Why?
|
| Narcotics | 1 | 2014 | 56 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 208 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 73 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 143 | 0.050 |
Why?
|
| Point Mutation | 1 | 2024 | 337 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Lamivudine | 1 | 2022 | 20 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2023 | 83 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 220 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 153 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 228 | 0.050 |
Why?
|
| Hypotension | 1 | 2014 | 177 | 0.050 |
Why?
|
| Middle Aged | 5 | 2015 | 27337 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 295 | 0.040 |
Why?
|
| Informed Consent | 1 | 2014 | 336 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 334 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 788 | 0.040 |
Why?
|
| Optic Nerve Glioma | 1 | 2001 | 21 | 0.040 |
Why?
|
| Disease Management | 1 | 2024 | 528 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 310 | 0.040 |
Why?
|
| United States | 3 | 2023 | 11159 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2010 | 258 | 0.040 |
Why?
|
| Probability | 1 | 2010 | 301 | 0.040 |
Why?
|
| Aged | 3 | 2011 | 20039 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 678 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 471 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 1383 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 21 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 775 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 115 | 0.040 |
Why?
|
| Death Certificates | 1 | 1998 | 11 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 193 | 0.040 |
Why?
|
| Cytokines | 1 | 2014 | 1316 | 0.030 |
Why?
|
| Isoelectric Focusing | 1 | 2017 | 23 | 0.030 |
Why?
|
| Saponins | 1 | 2017 | 20 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2011 | 12352 | 0.030 |
Why?
|
| Sulfites | 1 | 2017 | 27 | 0.030 |
Why?
|
| Canada | 1 | 1998 | 299 | 0.030 |
Why?
|
| Texas | 2 | 2007 | 3536 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2017 | 66 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 121 | 0.030 |
Why?
|
| Sex Factors | 1 | 2001 | 1292 | 0.030 |
Why?
|
| Patient Selection | 1 | 2010 | 698 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2035 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1807 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 310 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2022 | 3297 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 376 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 313 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 241 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2014 | 40 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 59 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 3143 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2015 | 177 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 802 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 104 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 505 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 229 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 192 | 0.030 |
Why?
|
| Intelligence | 1 | 2014 | 91 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 751 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 2566 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 510 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 183 | 0.020 |
Why?
|
| Incidence | 1 | 2001 | 3192 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2014 | 214 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 527 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1010 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 76 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 2865 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 3417 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 306 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 26 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 79 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 99 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 112 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 132 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 298 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1349 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 902 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 757 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 247 | 0.020 |
Why?
|
| SEER Program | 1 | 2007 | 200 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6167 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 409 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 542 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 2053 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2004 | 20 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2004 | 25 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 137 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 990 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2004 | 96 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1306 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 3653 | 0.010 |
Why?
|
| Ependymoma | 1 | 2004 | 138 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 5924 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 682 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1490 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 1343 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 1738 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 2602 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 3250 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6025 | 0.010 |
Why?
|